SCHEMBL24345378

SCHEMBL24345378

COc1cc(C(C)C)cc2c(OC)nccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
ACHE P22303 1/20 0.38
HDAC4 P56524 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
POLB P06746 1/20 0.36
TRPA1 O75762 3/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C19 P33261 2/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 2/20 0.35
PLAU P00749 1/20 0.34
FYN P06241 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24987964 0.82 ALOX15 (0.33) L3MBTL1ACHEALDH1A1SMN1; SMN2CYP1A2
SCHEMBL23717255 0.76 FGFR2 (0.32) FGFR2
SCHEMBL6380931 0.75 TRPA1 (0.43) FGFR2L3MBTL1ACHEALDH1A1SMN1; SMN2
SCHEMBL23847800 0.74 CCR1 (0.43) FGFR2L3MBTL1ACHEHDAC4HDAC8
SCHEMBL1811992 0.73 CA12 (0.49) L3MBTL1KDM4EALOX15MAPK1RAB9A
SCHEMBL23717023 0.72 MAOA (0.44) HDAC4HDAC8ALDH1A1SMN1; SMN2POLB
SCHEMBL24345363 0.72 SYK (0.59) FGFR2HDAC4HDAC8ALDH1A1SMN1; SMN2
SCHEMBL23717239 0.72 PDE10A (0.37) FGFR2HDAC4HDAC8ALDH1A1SMN1; SMN2
SCHEMBL8272297 0.72 PLAU (0.55) ALDH1A1TRPA1CYP1A2CYP3A4CYP2C19
SCHEMBL17132541 0.71 FGFR2 (0.54) FGFR2ACHEHDAC4HDAC8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230125803-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARM INC (US) 2023-04-27 US disclosed
US-20230125803-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARM INC (US) 2023-04-27 US disclosed
US-20230108803-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARMACEUTICALS, INC. 2023-04-06 US disclosed
US-20220119398-A1 HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119398-A1 HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS VIP, ACE, FURIN FGFR2 3061/4885L3MBTL1 4632/4885ACHE 2793/4885
US-20230108803-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ACE, HPRT1, ACE2 FGFR2 4035/4885L3MBTL1 3937/4885ACHE 1397/4885
US-20230125803-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ACE, HPRT1, ACE2 FGFR2 4035/4885L3MBTL1 3937/4885ACHE 1397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.